Data from Qualigen Therapeutics’ Lead Program QN-302 Accepted as Three Poster Presentations at AACR 2022 Conference
16 February 2022 - 1:15AM
Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company
focused on developing treatments for adult and pediatric cancers
with potential for Orphan Drug Designation, today announces that
three abstracts on aspects of the Company’s recently in-licensed
compound from University College -London, QN-302, have been
accepted as posters to be presented at the prestigious American
Association of Cancer Research (AACR) conference in April. QN-302
(previously known as SOP1812) is the Company’s genomic quadruplex
(G4)-selective transcription inhibitor platform being developed as
a potential treatment for pancreatic ductal adenocarcinoma (PDAC),
in addition to other tumors of high unmet clinical need.The three
abstracts include:
Abstract Number: |
2926 |
Title: |
“Structure-based design of quadruplex-binding small molecule
compounds: The essential role of water molecules” |
Lead Author: |
Dr. Stephen Neidle |
Session Title: |
Structural and Chemical Biology |
Session Date and Time: |
Tuesday Apr 12, 2022 9:00 AM - 12:30 PM CDT |
|
|
|
|
Abstract Number: |
4069 |
Title: |
“The
potent quadruplex-binding compound SOP1812 shows anti-tumor
activity in patient-derived in vivo models of pancreatic
cancer” |
Lead Author: |
Dr. Stephen Neidle |
Session Title: |
New Chemotherapy Agents |
Session Date and Time: |
Wednesday Apr 13, 2022 9:00 AM - 12:30 PM CDT |
|
|
|
|
Abstract Number: |
4068 |
Title: |
“The
potent quadruplex-binding compound SOP1812 shows potent
anti-proliferative activity in a prostate cancer cell panel and
anti-tumor activity in an in vivo model of metastatic
prostate cancer” |
Lead Author: |
Dr. Stephen Neidle |
Session Title: |
New Chemotherapy Agents |
Session Date and Time: |
Wednesday Apr 13, 2022 9:00 AM - 12:30 PM CDT |
|
|
The AACR Conference, being held in New Orleans
from April 8-13, 2022, is the focal point of the cancer research
community, where scientists, clinicians, other health care
professionals, survivors, patients, and advocates gather to share
the latest advances in cancer science and medicine.
About Qualigen
Therapeutics, Inc.
Qualigen Therapeutics, Inc. is a biotechnology
company focused on developing treatments for cancer, as well as
maintaining and expanding its core FDA-cleared FastPack® System,
which has been used successfully in diagnostics for 20 years. Our
investigational QN-302 compound is a small molecule selective
transcription inhibitor with strong binding affinity to G4s
prevalent in cancer cells; such binding could, by stabilizing the
G4s against “unwinding,” help inhibit cancer cell proliferation.
Our investigational QN-247 compound inhibits nucleolin, a key
multi-functional regulatory protein that is overexpressed in cancer
cells; QN-247 may be able to inhibit the cells’ proliferation.
QN-247 has shown promise in preclinical studies for the treatment
of acute myeloid leukemia (AML). The investigational compounds
within Qualigen’s RAS-F family of RAS oncogene protein-protein
interaction inhibitor small molecules are believed to inhibit or
block the binding of mutated RAS genes’ proteins to their effector
proteins, thereby leaving the proteins from the mutated RAS unable
to cause further harm. In theory, such mechanism of action may be
effective in the treatment of about one quarter of all cancers,
including certain forms of pancreatic, colorectal, and lung
cancers. In addition to its oncology drug pipeline, Qualigen has an
established diagnostics business which manufactures and distributes
proprietary and highly accurate rapid blood testing systems to
physician offices and small hospitals for the management of
prostate cancer and other diseases and health conditions.
For more information about Qualigen Therapeutics, Inc., please
visit www.qualigeninc.com.
Forward-Looking Statements
This news release contains forward-looking
statements by Qualigen that involve risks and uncertainties and
reflect the Company's judgment as of the date of this release.
These statements include those related to the Company's prospects
and strategy for the development of therapeutic drug candidates.
Actual events or results may differ from the Company's
expectations. For example, there can be no assurance that the
Company will successfully develop any drugs (including QN-302,
QN-247 and RAS-F); that preclinical development of the Company's
drugs (including QN-302, QN-247 and RAS-F, and its deprioritized
infectious-disease drug candidate QN-165) will be completed on any
projected timeline or will be successful; that any clinical trials
will be approved to begin by or will proceed as contemplated by any
projected timeline, or at all; that any future clinical trial data
will be favorable or that such trials will confirm any improvements
over other products or lack negative impacts; that any drugs will
receive required regulatory approvals (or Fast Track designation or
Orphan Drug status) or that they will be commercially successful;
that patents will issue on the Company's owned and in-licensed
patent applications; that such patents, if any, and the Company's
currently owned and inlicensed patents would prevent competition;
that the Company will be able to procure or earn sufficient working
capital to complete the development, testing and launch of the
Company's prospective therapeutic products (including QN-302,
QN-247 and RAS-F, and QN-165); or that the Company will be able to
maintain or expand market demand and/or market share for the
Company's diagnostic products. The Company's stock price could be
harmed if any of the events or trends contemplated by the
forward-looking statements fails to occur or is delayed or if any
actual future event otherwise differs from expectations. Additional
information concerning these and other risk factors affecting the
Company's business can be found in the Company's prior filings with
the Securities and Exchange Commission, including its most recent
Form 10-K, all of which are available at www.sec.gov.
The Company disclaims any intent or obligation
to update these forward-looking statements beyond the date of this
news release, except as required by law. This caution is made under
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.
Investor Relations:
David Kugelman Atlanta Capital Partners, LLC(404) 856-9157 or
(866) 692-6847 Toll Free - U.S. & Canadadk@atlcp.com
Tony SchorInvestor Awareness, Inc.(847)
971-0922tony@investorawareness.com
Media:
Jules AbrahamJQA Partners,
Inc.917-885-7378jabraham@jqapartners.com
Source: Qualigen Therapeutics, Inc.
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Apr 2024 to May 2024
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From May 2023 to May 2024